LEADER 04007nam  2201033z- 450 
001 9910557291103321
005 20210501
035   $a(CKB)5400000000041128
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69153
035   $a(oapen)doab69153
035   $a(EXLCZ)995400000000041128
100   $a20202105d2020      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aMycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020
215   $a1 online resource (128 p.)
311 08$a3-03936-658-0 
311 08$a3-03936-659-9 
330   $aTuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB) and it represents a persistent public health threat for a number of complex biological and sociological reasons. According to the most recent Global Tuberculosis Report (2019) edited by the World Health Organization (WHO), TB is considered the ninth cause of death worldwide and the leading cause of mortality by a single infectious agent, with the highest rate of infections and death toll rate mostly concentrated in developing and low-income countries. We present here the editorial section to the Special Issue entitled "Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment" that includes 7 research articles and a review. The scientific contributions included in the Special Issue mainly focus on the characterization of MTB strains emerging in TB endemic countries as well as on multiple mechanisms adopted by the bacteria to resist and to adapt to antitubercular therapies.
606   $aBiology, life sciences$2bicssc
606   $aResearch & information: general$2bicssc
610   $aantitubercular drug discovery
610   $aantitubercular treatments
610   $aapoptosis
610   $aBeijing B0/W148
610   $aBeijing genotype
610   $aBM-MSCs
610   $abone-homing
610   $aCD38
610   $aCentral Asia Outbreak
610   $acytokine
610   $adrug discovery
610   $adrug resistance
610   $adrug target
610   $aeffector
610   $aefflux
610   $agene expression
610   $aHLA-DR
610   $ahost-pathogen interactions
610   $aIL-18
610   $aIL-18BP
610   $aIL-18R
610   $aimidazo[1,2-b][1,2,4,5]tetrazine
610   $aimmune activation
610   $aimmune response
610   $alatent tuberculosis
610   $aline probe assay
610   $aliposomes
610   $aM. tuberculosis
610   $amacrophage
610   $aMDR-TB
610   $amicroRNA
610   $aMmpS5-MmpL5
610   $aMtb
610   $amurine infection model
610   $aMycobacterium
610   $aMycobacterium avium
610   $aMycobacterium smegmatis
610   $aMycobacterium tuberculosis
610   $aomics analysis
610   $apre-XDR-TB
610   $arelapse
610   $asecond-line drugs
610   $astem cell niche
610   $asubtractive genomics
610   $asystem analysis
610   $aTB treatment
610   $atreatment response
610   $atuberculosis
610   $auncharacterized proteins
610   $aunique metabolic pathways
610   $aVirulence
610   $aXDR-TB
615  7$aBiology, life sciences
615  7$aResearch & information: general
700   $aFerraris$b Davide Maria$4edt$01296151
702   $aMiggiano$b Riccardo$4edt
702   $aRizzi$b Menico$4edt
702   $aFerraris$b Davide Maria$4oth
702   $aMiggiano$b Riccardo$4oth
702   $aRizzi$b Menico$4oth
906   $aBOOK
912   $a9910557291103321
996   $aMycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment$93023812
997   $aUNINA